ZA200806288B - Rage fusion proteins and methods of use - Google Patents
Rage fusion proteins and methods of useInfo
- Publication number
- ZA200806288B ZA200806288B ZA200806288A ZA200806288A ZA200806288B ZA 200806288 B ZA200806288 B ZA 200806288B ZA 200806288 A ZA200806288 A ZA 200806288A ZA 200806288 A ZA200806288 A ZA 200806288A ZA 200806288 B ZA200806288 B ZA 200806288B
- Authority
- ZA
- South Africa
- Prior art keywords
- methods
- fusion proteins
- rage fusion
- rage
- proteins
- Prior art date
Links
- 102000037865 fusion proteins Human genes 0.000 title 1
- 108020001507 fusion proteins Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/41—Detecting, measuring or recording for evaluating the immune or lymphatic systems
- A61B5/412—Detecting or monitoring sepsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/41—Detecting, measuring or recording for evaluating the immune or lymphatic systems
- A61B5/413—Monitoring transplanted tissue or organ, e.g. for possible rejection reactions after a transplant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01J—MEASUREMENT OF INTENSITY, VELOCITY, SPECTRAL CONTENT, POLARISATION, PHASE OR PULSE CHARACTERISTICS OF INFRARED, VISIBLE OR ULTRAVIOLET LIGHT; COLORIMETRY; RADIATION PYROMETRY
- G01J3/00—Spectrometry; Spectrophotometry; Monochromators; Measuring colours
- G01J3/28—Investigating the spectrum
- G01J3/44—Raman spectrometry; Scattering spectrometry ; Fluorescence spectrometry
- G01J3/4412—Scattering spectrometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/47—Scattering, i.e. diffuse reflection
- G01N21/4795—Scattering, i.e. diffuse reflection spatially resolved investigating of object in scattering medium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/40—Detecting, measuring or recording for evaluating the nervous system
- A61B5/4076—Diagnosing or monitoring particular conditions of the nervous system
- A61B5/4088—Diagnosing of monitoring cognitive diseases, e.g. Alzheimer, prion diseases or dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/636—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited using an arrangement of pump beam and probe beam; using the measurement of optical non-linear properties
- G01N2021/638—Brillouin effect, e.g. stimulated Brillouin effect
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/38—Pediatrics
- G01N2800/385—Congenital anomalies
- G01N2800/387—Down syndrome; Trisomy 18; Trisomy 13
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Pathology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Heart & Thoracic Surgery (AREA)
- Biochemistry (AREA)
- Surgery (AREA)
- Medical Informatics (AREA)
- Vascular Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- General Physics & Mathematics (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Transplantation (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US77161906P | 2006-02-09 | 2006-02-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200806288B true ZA200806288B (en) | 2010-03-31 |
Family
ID=38349553
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200806288A ZA200806288B (en) | 2006-02-09 | 2008-07-18 | Rage fusion proteins and methods of use |
Country Status (16)
Country | Link |
---|---|
US (1) | US20090004190A1 (ja) |
EP (1) | EP1989227A2 (ja) |
JP (1) | JP2007215543A (ja) |
KR (1) | KR20080105066A (ja) |
CN (1) | CN101410411A (ja) |
AR (1) | AR059377A1 (ja) |
AU (1) | AU2007215503A1 (ja) |
BR (1) | BRPI0707640A2 (ja) |
CA (1) | CA2638907A1 (ja) |
EA (1) | EA015657B1 (ja) |
IL (1) | IL192581A0 (ja) |
NL (1) | NL2000476C2 (ja) |
NZ (1) | NZ569545A (ja) |
TW (1) | TW200806690A (ja) |
WO (1) | WO2007094926A2 (ja) |
ZA (1) | ZA200806288B (ja) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA012586B1 (ru) * | 2004-08-03 | 2009-10-30 | Транстек Фарма, Инк. | Rage-слитые белки и способы их применения |
EA012082B1 (ru) * | 2004-08-03 | 2009-08-28 | Транстек Фарма, Инк. | Белки слияния на основе rage и способы их использования |
US7957931B2 (en) * | 2005-12-23 | 2011-06-07 | Gcoder Systems Ab | Positioning pattern |
US7981424B2 (en) * | 2006-05-05 | 2011-07-19 | Transtech Pharma, Inc. | RAGE fusion proteins, formulations, and methods of use thereof |
WO2008100470A2 (en) * | 2007-02-15 | 2008-08-21 | Transtech Pharma, Inc. | Rage - immunoglobulin fusion proteins |
NL2001556C2 (nl) * | 2008-05-06 | 2009-05-07 | Transtech Pharma | Rage-fusie-eiwitten, preparaten en werkwijzen voor het gebruik ervan. |
NL2001552C2 (nl) * | 2008-05-06 | 2009-05-07 | Transtech Pharma | Rage-fusie-eiwitten, preparaten en werkwijzen voor het gebruik ervan. |
NL2001551C2 (nl) * | 2008-05-06 | 2009-05-07 | Transtech Pharma | Rage-fusie-eiwitten, preparaten en werkwijzen voor het gebruik ervan. |
NL2001558C2 (nl) * | 2008-05-06 | 2009-05-07 | Transtech Pharma | Rage-fusie-eiwitten, preparaten en werkwijzen voor het gebruik ervan. |
NL2001554C2 (nl) * | 2008-05-06 | 2009-05-07 | Transtech Pharma | Rage-fusie-eiwitten, preparaten en werkwijzen voor het gebruik ervan. |
NL2001553C2 (nl) * | 2008-05-06 | 2009-05-07 | Transtech Pharma | Rage-fusie-eiwitten, preparaten en werkwijzen voor het gebruik ervan. |
NL2001555C2 (nl) * | 2008-05-06 | 2009-05-07 | Transtech Pharma | Rage-fusie-eiwitten, preparaten en werkwijzen voor het gebruik ervan. |
NL2001557C2 (nl) * | 2008-05-06 | 2009-05-07 | Transtech Pharma | Rage-fusie-eiwitten, preparaten en werkwijzen voor het gebruik ervan. |
EP2421892A1 (en) * | 2009-04-20 | 2012-02-29 | Pfizer Inc. | Control of protein glycosylation and compositions and methods relating thereto |
US20110137178A1 (en) * | 2009-10-06 | 2011-06-09 | The General Hospital Corporation | Devices and methods for imaging particular cells including eosinophils |
CN105037538A (zh) * | 2015-08-31 | 2015-11-11 | 武汉班科生物技术有限责任公司 | 优化的Fc片段及其优化方法和应用 |
WO2017189821A1 (en) * | 2016-04-29 | 2017-11-02 | Bio-Rad Laboratories, Inc. | Dimeric proteins for specific targeting of nucleic acid sequences |
US10143187B2 (en) | 2017-02-17 | 2018-12-04 | Denali Therapeutics Inc. | Transferrin receptor transgenic models |
US10457717B2 (en) | 2017-02-17 | 2019-10-29 | Denali Therapeutics Inc. | Engineered polypeptides |
JP2020508053A (ja) * | 2017-02-17 | 2020-03-19 | デナリ セラピューティクス インコーポレイテッドDenali Therapeutics Inc. | 操作されたポリペプチド |
Family Cites Families (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4867973A (en) * | 1984-08-31 | 1989-09-19 | Cytogen Corporation | Antibody-therapeutic agent conjugates |
US6018026A (en) * | 1988-01-22 | 2000-01-25 | Zymogenetics, Inc. | Biologically active dimerized and multimerized polypeptide fusions |
US5567584A (en) * | 1988-01-22 | 1996-10-22 | Zymogenetics, Inc. | Methods of using biologically active dimerized polypeptide fusions to detect PDGF |
NZ235148A (en) * | 1989-09-05 | 1991-12-23 | Immunex Corp | Tumour necrosis factor receptor protein and dna sequences |
MX9204374A (es) * | 1991-07-25 | 1993-03-01 | Idec Pharma Corp | Anticuerpo recombinante y metodo para su produccion. |
SE9201073D0 (sv) * | 1992-04-03 | 1992-04-03 | Kabi Pharmacia Ab | Protein formulation |
US5298523A (en) * | 1992-12-14 | 1994-03-29 | Harbor Branch Oceanographic Institution, Inc. | Method for treating transplant patients using mycalamide compounds |
PT808163E (pt) * | 1995-01-18 | 2003-12-31 | Alteon Inc | Uso de compostos de tiazolio para prevencao e inversao da formacao de produtos finais com glicosilacao avancada |
FI119756B (fi) * | 1995-01-18 | 2009-03-13 | Alteon Inc | Tiatsoliumyhdisteiden käyttö pitkälle edenneen glykosylaation lopputuotteiden muodostumisen estossa ja suunnan muutoksessa |
US5656261A (en) * | 1995-01-18 | 1997-08-12 | The Picower Institute For Medical Research | Preventing and reversing advanced glycosylation endproducts |
JPH11504316A (ja) * | 1995-04-05 | 1999-04-20 | ザ ピコワー インスティテュート フォア メディカル リサーチ | 進行性グリコシル化終末産物に結合する薬剤及びその使用方法 |
US5747035A (en) * | 1995-04-14 | 1998-05-05 | Genentech, Inc. | Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor |
US6267958B1 (en) * | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
US5864018A (en) * | 1996-04-16 | 1999-01-26 | Schering Aktiengesellschaft | Antibodies to advanced glycosylation end-product receptor polypeptides and uses therefor |
US6555651B2 (en) * | 1997-10-09 | 2003-04-29 | The Trustees Of Columbia University In The City Of New York | Ligand binding site of rage and uses thereof |
US7081241B1 (en) * | 1998-10-06 | 2006-07-25 | The Trustees Of Columbia University In The City Of New York | Extracellular rage binding protein (EN-RAGE) and uses thereof |
US6790443B2 (en) * | 1996-11-22 | 2004-09-14 | The Trustees Of Columbia University In The City Of New York | Method for treating symptoms of diabetes |
US7258857B2 (en) * | 1996-11-22 | 2007-08-21 | The Trustees Of Columbia University In The City Of New York | Rage-related methods for treating inflammation |
US7101838B2 (en) * | 1997-08-05 | 2006-09-05 | The Trustees Of Columbia University In The City Of New York | Method to prevent accelerated atherosclerosis using (sRAGE) soluble receptor for advanced glycation endproducts |
ZA988461B (en) * | 1997-09-18 | 1999-03-30 | Idec Pharma Corp | Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis |
US6380165B1 (en) * | 1997-09-19 | 2002-04-30 | The Picower Institute For Medical Research | Immunological advanced glycation endproduct crosslink |
US6761888B1 (en) * | 2000-05-26 | 2004-07-13 | Neuralab Limited | Passive immunization treatment of Alzheimer's disease |
US6323218B1 (en) * | 1998-03-11 | 2001-11-27 | The General Hospital Corporation | Agents for use in the treatment of Alzheimer's disease |
US6465422B1 (en) * | 1998-04-17 | 2002-10-15 | The Trustees Of Columbia University In The City Of New York | Method for inhibiting tumor invasion or spreading in a subject |
US6753150B2 (en) * | 1998-10-05 | 2004-06-22 | The Trustees Of Columbia University In The City Of New York | Method for determining whether a compound is capable of inhibiting the interaction of a peptide with rage |
NZ511055A (en) * | 1998-10-05 | 2003-10-31 | Pharmexa As | Novel methods for therapeutic vaccination |
ES2299267T3 (es) * | 1998-10-06 | 2008-05-16 | The Trustees Of Columbia University In The City Of New York | Nueva proteina extracelular ligante de rage (en-rage) y sus usos. |
US6197294B1 (en) * | 1998-10-26 | 2001-03-06 | Neurotech S.A. | Cell surface molecule-induced macrophage activation |
US6787566B2 (en) * | 1999-04-05 | 2004-09-07 | City Of Hope | Breakers of advanced glycation endproducts |
US6605642B2 (en) * | 1999-04-05 | 2003-08-12 | City Of Hope | Inhibitors of formation of advanced glycation endproducts (AGES) |
US6939545B2 (en) * | 1999-04-28 | 2005-09-06 | Genetics Institute, Llc | Composition and method for treating inflammatory disorders |
AU6766800A (en) * | 1999-08-13 | 2001-03-13 | Trustees Of Columbia University In The City Of New York, The | Methods of inhibiting binding of beta-sheet fibril to rage and consequences thereof |
US20050170382A1 (en) * | 1999-10-06 | 2005-08-04 | The Trustees Of Columbia University In The City Of New York. | RAGE-related compositions |
EP1252305A2 (en) * | 1999-12-08 | 2002-10-30 | Genset | Full-length human cdnas encoding potentially secreted proteins |
JP3920641B2 (ja) * | 2000-04-14 | 2007-05-30 | ナイアダイン コーポレーション | タンパク質−後期糖化反応生成物(タンパク質−age)形成の調節因子を同定する方法 |
US6908741B1 (en) * | 2000-05-30 | 2005-06-21 | Transtech Pharma, Inc. | Methods to identify compounds that modulate RAGE |
US6825164B1 (en) * | 2000-08-14 | 2004-11-30 | The Trustees Of Columbia University In The City Of New York | Method to increase cerebral blood flow in amyloid angiopathy |
US6563015B1 (en) * | 2000-08-14 | 2003-05-13 | The Trustees Of Columbia University In The City Of New York | Transgenic mice over-expressing receptor for advanced glycation endproduct (RAGE) and mutant APP in brain and uses thereof |
BR0114411A (pt) * | 2000-10-02 | 2006-05-09 | Reddy Us Therapeutics Inc | métodos e composições para o tratamento de doenças inflamatórias |
AU2002213192A1 (en) * | 2000-10-13 | 2002-04-22 | The Trustees Of Columbia University In The City Of New York | A method for inhibiting new tissue growth in blood vessels in a patient subjected to blood vessel injury |
US20050244849A1 (en) * | 2000-12-15 | 2005-11-03 | Genetics Institute, Llc | Screening assays for rheumatoid arthritis |
JP2005501222A (ja) * | 2000-12-29 | 2005-01-13 | レディ ユーエス セラピューティクス インコーポレイテッド | 炎症応答を調節する化合物を検出するための方法及び組成物 |
PL362324A1 (en) * | 2001-02-19 | 2004-10-18 | Merck Patent Gmbh | Artificial fusion proteins with reduced immunogenicity |
JP3837494B2 (ja) * | 2001-03-19 | 2006-10-25 | 国立大学法人金沢大学 | 可溶型rageタンパク質 |
US7304034B2 (en) * | 2001-05-15 | 2007-12-04 | The Feinstein Institute For Medical Research | Use of HMGB fragments as anti-inflammatory agents |
FR2828186A1 (fr) * | 2001-08-06 | 2003-02-07 | Memscap | Composant microelectromecanique |
US20060140933A1 (en) * | 2002-08-16 | 2006-06-29 | Wyeth And Imperial College Innovations Limited | Compositions and methods for treating rage-associated disorders |
US8067371B2 (en) * | 2003-05-09 | 2011-11-29 | The Trustees Of Columbia University In The City Of New York | RAGE G82S-related methods and compositions for treating inflammatory disorders |
WO2005021710A2 (en) * | 2003-06-02 | 2005-03-10 | University Of Miami | Chimeric molecules and methods of use |
US7111871B2 (en) * | 2003-08-02 | 2006-09-26 | General Motors Corporation | Automotive vehicle air bag system |
CA2536512A1 (en) * | 2003-09-05 | 2005-03-17 | The Trustees Of Columbia University In The City Of New York | Rage-related methods and compositions for treating glomerular injury |
WO2005042032A1 (en) * | 2003-10-31 | 2005-05-12 | The Trustees Of Columbia University In The City Of New York | Methods for treating multiple sclerosis |
BRPI0512944A (pt) * | 2004-07-02 | 2008-04-15 | Creabilis Therapeutics Spa | agentes terapêuticos para o tratamento de patologias relacionadas com hmgb1 |
US7470521B2 (en) * | 2004-07-20 | 2008-12-30 | Critical Therapeutics, Inc. | RAGE protein derivatives |
EA012082B1 (ru) * | 2004-08-03 | 2009-08-28 | Транстек Фарма, Инк. | Белки слияния на основе rage и способы их использования |
EA012586B1 (ru) * | 2004-08-03 | 2009-10-30 | Транстек Фарма, Инк. | Rage-слитые белки и способы их применения |
EP1799700A4 (en) * | 2004-09-27 | 2009-02-11 | Centocor Inc | SRAGE MIMETIC BODIES, COMPOSITIONS, PROCESSES AND USES |
US20080207499A1 (en) * | 2005-06-29 | 2008-08-28 | Gaetano Barile | Rage-related methods for treating and preventing diabetic retinopathy |
US7981424B2 (en) * | 2006-05-05 | 2011-07-19 | Transtech Pharma, Inc. | RAGE fusion proteins, formulations, and methods of use thereof |
WO2008100470A2 (en) * | 2007-02-15 | 2008-08-21 | Transtech Pharma, Inc. | Rage - immunoglobulin fusion proteins |
US7982424B2 (en) * | 2007-08-09 | 2011-07-19 | Seiko Epson Corporation | Document reading apparatus, document reading method, and program for reading document |
-
2007
- 2007-01-23 EP EP07716896A patent/EP1989227A2/en not_active Withdrawn
- 2007-01-23 CA CA002638907A patent/CA2638907A1/en not_active Withdrawn
- 2007-01-23 AU AU2007215503A patent/AU2007215503A1/en not_active Abandoned
- 2007-01-23 EA EA200870244A patent/EA015657B1/ru not_active IP Right Cessation
- 2007-01-23 NZ NZ569545A patent/NZ569545A/en not_active Application Discontinuation
- 2007-01-23 CN CNA2007800110207A patent/CN101410411A/zh not_active Withdrawn
- 2007-01-23 WO PCT/US2007/001686 patent/WO2007094926A2/en active Application Filing
- 2007-01-23 KR KR1020087021892A patent/KR20080105066A/ko not_active IP Right Cessation
- 2007-01-23 US US12/162,658 patent/US20090004190A1/en not_active Abandoned
- 2007-01-23 BR BRPI0707640-1A patent/BRPI0707640A2/pt not_active Application Discontinuation
- 2007-02-07 NL NL2000476A patent/NL2000476C2/nl not_active IP Right Cessation
- 2007-02-08 JP JP2007029408A patent/JP2007215543A/ja not_active Withdrawn
- 2007-02-08 AR ARP070100534A patent/AR059377A1/es unknown
- 2007-02-09 TW TW096104916A patent/TW200806690A/zh unknown
-
2008
- 2008-07-02 IL IL192581A patent/IL192581A0/en unknown
- 2008-07-18 ZA ZA200806288A patent/ZA200806288B/xx unknown
Also Published As
Publication number | Publication date |
---|---|
EP1989227A2 (en) | 2008-11-12 |
EA200870244A1 (ru) | 2009-02-27 |
BRPI0707640A2 (pt) | 2011-05-10 |
NL2000476C2 (nl) | 2008-04-08 |
WO2007094926A3 (en) | 2007-10-18 |
KR20080105066A (ko) | 2008-12-03 |
JP2007215543A (ja) | 2007-08-30 |
NL2000476A1 (nl) | 2007-08-10 |
AU2007215503A1 (en) | 2007-08-23 |
CN101410411A (zh) | 2009-04-15 |
CA2638907A1 (en) | 2007-08-23 |
EA015657B1 (ru) | 2011-10-31 |
US20090004190A1 (en) | 2009-01-01 |
NZ569545A (en) | 2011-11-25 |
AU2007215503A8 (en) | 2008-09-11 |
AR059377A1 (es) | 2008-03-26 |
WO2007094926A2 (en) | 2007-08-23 |
TW200806690A (en) | 2008-02-01 |
IL192581A0 (en) | 2009-02-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200806288B (en) | Rage fusion proteins and methods of use | |
IL180554A0 (en) | Rage fusion proteins and methods of use | |
ZA200700641B (en) | Rage fusion proteins and methods of use | |
ZA200809394B (en) | Rage fusion proteins, formulations, and methods of use thereof | |
IL196243A0 (en) | Fused heterocyclic derivatives and methods of use | |
EP2057465A4 (en) | SPECIFIC ORGAN PROTEINS AND METHODS OF USE | |
LT2650020T (lt) | Trimerinio ox40-immunoglobulino sulietas baltymas ir naudojimo būdai | |
EP2007884A4 (en) | ENZYMATIC FUSION PROTEINS AND THEIR USE | |
HK1137031A1 (en) | Smoothened polypeptides and methods of use smoothened | |
EP2102355A4 (en) | PROTEINS AND PEPTIDES WITH EXTENDED ACTION AND METHODS OF PRODUCTION AND USE THEREOF | |
IL198397A0 (en) | Anilinopiperazine derivatives and methods of use thereof | |
EP1959997A4 (en) | ANTAGONISTS OF HMGB1 AND / OR RAGE AND METHOD OF USE THEREOF | |
IL198020A0 (en) | Anti-cd20 antibodies and methods of use | |
IL195573A0 (en) | Fc??RIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF | |
IL200808A0 (en) | Soluble il-17ra/rc fusion proteins and related methods | |
IL194161A0 (en) | Tetramerizing polypeptides and methods of use | |
EP2021555A4 (en) | STRUCTURAL ELEMENT AND METHODS OF USE THEREOF | |
EP2029799A4 (en) | THERMOSTABLE PROTEINS AND METHODS FOR PREPARING AND USING SAME | |
EP2167111A4 (en) | POLYPEPTIDES AND METHOD OF USE | |
IL206334A0 (en) | Sarp-i fusion proteins and their use | |
ZA200808656B (en) | Enzyme fusion proteins and their use |